Navigation Links
LA BioMed researchers report on promising new therapy for devastating genetic disorder
Date:2/12/2014

LOS ANGELES (Feb. 12, 2014) A promising new therapy has for the first time reduced damage to the brain that can be caused by Sanfilippo B (MPS IIIB), a rare and devastating genetic disease, Los Angeles Biomedical Research Institute (LA BioMed) researchers will report today in a presentation at the Lysosomal Disease Network's 10th Annual WORLD Symposium.

Sanfilippo B syndrome is a lysosomal storage disease belonging to the group of mucopolysaccharidoses (MPS) that is characterized by severe and rapid intellectual deterioration. LA BioMed pioneered the research that led to the first enzyme replacement therapy for MPS I, Aldurazyme, which has saved hundreds of lives in the nearly 11 years since it was approved by the Food and Drug Administration.

LA BioMed's MPS Research Laboratory reported the results of its latest study for treating Sanfilippo B syndrome in a disease model that employed recombinant human "NAGLU-IGF2" (a novel fusion protein of alpha-N-acetyglucosaminidase, or NAGLU, coupled to a peptide derived from the insulin-like growth factor, IGF2). The fusion protein was produced by BioMarin Pharmaceutical Inc.

LA BioMed researcher Shih-hsin Kan reported that the laboratory's tests found NAGLU-IGF2 is taken up by neurons in the disease model, which then reduces brain damage by reversing heparan sulfate storage one of the causes of damage to the brain in patients with Sanfilippo B syndrome. The researchers concluded that NAGLU-IGF2 can be the basis for enzyme replacement therapy for Sanfilippo B syndrome.

"This is an exciting new development that needs to be examined further to determine its effectiveness in patients with Sanfilippo B syndrome who currently have no therapies available to reduce the damage to their brains," said Patricia Dickson, MD, director of the MPS Research Laboratory at LA BioMed. "We look forward to continuing our partnership with BioMarin in developing therapies for MPS."

BioMarin announced Tuesday that it has developed BMN 250, a manufactured form of NAGLU-IGF2, for the treatment of Sanfilippo B syndrome and expects to initiate clinical studies with BMN 250 in mid-2015.


'/>"/>

Contact: Laura Mecoy
lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Pitts Center for Medical Innovation announces pilot funding for biomedical technology
2. New biomedical diagnostics using personalized 3-D imaging
3. NCCS and Clearbridge Biomedics open the regions first circulating tumor cell center
4. LA BioMed study finds daily antibiotics most effective in preventing recurrent urinary tract infection
5. A New Player In Biomedical Equipment Opens Headquarters in San Diego
6. Four Researchers from Icahn School of Medicine at Mount Sinai Among the 400 Most Highly Influential Biomedical Researchers in the World
7. CHI and PwC US Release 2014 California Biomedical Industry Report
8. New materials with potential biomedical applications
9. California Healthcare Institute to Release 2014 California Biomedical Industry Report
10. Animal, human health benefits anticipated from universitys premier biomedical instrument
11. MU receives $1.1 million training grant to increase diversity in biomedical sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... Dr. Farhan Qureshi is an esteemed dentist who offers a ... practice has two convenient office locations in Alexandria and Arlington, Virginia. Recently, Find Local ... Alexandria area. This award confirms the fact that Dr. Qureshi’s patients have left ...
(Date:1/18/2017)... ... 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), a ... Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. The ... thought leader interaction in, live video and interactive digital platforms. , In making ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... of the revolutionary Active Brake Technology (ABT), an innovative braking system that allows ... Active Brake Technology addresses one of the biggest concerns of beginner and intermediate ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s resolutions? ... the perfect time for a reset. The U.S. Apple Association agrees and recommends ... of the factors that contribute to heart disease. , The U.S. Apple Association – ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, but it ... Dentists have several general anesthesia alternatives and finding the right option can result in ... in Tokyo, Japan wanted to find out which anesthetic was the better choice in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... January 17, 2017 Management to Discuss ... Ltd.   KIT-302 Development On Track For An ... in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an ... Monday, January 23 rd at 8:30am Eastern Time to discuss the recent ...
(Date:1/17/2017)... , Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... patient has been enrolled in a Phase 3 clinical ... best supportive care (BSC) in the prevention of hepatic ... hematopoietic stem cell transplant (HSCT) who are at high ... The defibrotide clinical trial will be conducted across approximately ...
(Date:1/17/2017)... 2017  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, plans to announce ... 2016 after the market closes on Wednesday, February 1, ... p.m. ET that day to discuss those results. ... 407-8037 or (201) 689-8037.  For 72 hours following the ...
Breaking Medicine Technology: